Search results for Bemarituzumab
Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade, ProteoGenix, PX-TA1492
Description of Bemarituzumab Biosimilar - Anti-FGFR2 mAb - Research Grade Bemarituzumab Biosimilar – Anti- FGFR2 mAb – Research Grade About Bemarituzumab biosimilar Bemarituzumab is a humanized monoclonal antibody targeting the human fibroblast growth factor receptor 2b (FGFR2b). This humanized glycosylated biosimilar belong to the family of immunoglobulin G1- type. It blocks FGF ligand binding to the receptor, which causes the inhibition of downstream signaling pathways and promotes Antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab induces receptor internalization and degradation. About FGFR2b and FGF/FGFR pathway FGFR2b is an isoform of fibroblast growth factor receptors. They are four signaling tyrosine kinase FGF receptors mediating interactions between cytosolic environment and mesenchyme. Activated FGFRs can phosphorylate tyrosine residues which are mediating specifically interaction with cytosolic adaptor proteins. FGFR2b receptor is overexpressed in 30% of HER2-negative Gastric and Gastroesophageal Cancers. Bemarituzumab is designed to target these specific cancer subtypes, which are using the FGF/FGFR pathway to promote transformation and proliferation of cells into tumors and to promote angiogenesis. A research grade biosimilar Bemarituzumab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.
Host
Reactivity
Applications
Conjugation
Bemarituzumab, Abbexa, abx831451
Bemarituzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FGFR2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Bemarituzumab is a subtype-selective humanized monoclonal antibody against FGFR2b. The FIGH study aims to evaluate the efficacy of its combined chemotherapy for untreated advanced gastric cancer or gastroesophageal junction cancer.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Bemarituzumab Biosimilar - Research Grade, ichor.bio, ICH5053
Detects human FGFR2b. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bemarituzumab.
Host
Human IgG1
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.